We have read the paper by Montopoli et al.1 reporting the possible coronavirus disease-19 (COVID-19) protective role of antiestrogenic therapy in women treated for breast and ovarian cancer. Since the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection outbreak in December 2019, it has been shown that the majority of patients hospitalized for COVID-19 are males.2 These observations, confirmed worldwide, defined a clear sex difference associated with COVID-19 morbidity and mortality.2 In particular, the prevalence of pre-menopausal women among COVID-19 patients is very low,3 suggesting a ‘protective’ role of estrogens linked to different mechanisms of action such as the reduction of expression of angiotensin-converting enzyme 2 (the SARS-CoV-2 receptor on target cells) by estradiol, the modulation of the immune response by estrogen, and the presence of different X-linked genes involved in inflammatory response.3 The ‘protective’ role of estrogens in SARS-CoV-2 infection has been reported previously during SARS-CoV and Middle East respiratory syndrome coronavirus (MERS) epidemics.3 Furthermore, animal studies showed that estradiol reduction or the use of estrogen receptor antagonists favored SARS-CoV infection.3
Thus, data regarding COVID-19 patients seem to indicate a gender difference in morbidity and mortality with males being more susceptible to SARS-CoV-2 infection complications and females, above all in pre-menopausal women, being protected from the severe forms of the disease. In this regard, as reported by the Italian National Institute of Health (10 February 2021),4 SARS-CoV-2-positive women aged 60-69 years (menopausal) show a lethality index 15 times higher than that of SARS-CoV-2-positive women aged 40-49 years [non-menopausal, odds ratio (OR) 15.5, 95% confidence interval 13.6-17.9, P < 0.0001], with a much higher OR if we consider women younger than 40 years of age.
Furthermore, when considering SARS-CoV-2 infection, Montopoli et al. compared hormone-driven cancer patients treated with selective estrogen receptor modulators (SERMs), aromatase inhibitors, and luteinizing hormone-releasing hormone agonist (LH-RHa). These drugs do not function in the same way in the modulation of estrogen receptor, since SERMs are a class of drugs that act on the estrogen receptor but can function as an agonist or antagonist differently in various tissues, thus selectively inhibiting estrogen action or stimulating it.5 On the contrary, aromatase inhibitors and LH-RHa do not have the same selective effects of SERMs, leading to the same effect in all tissues by suppressing estrogen production. Thus, data from SERM-treated cancer patients could not be fully comparable with those from patients treated with aromatase inhibitors and LH-RHa.5
With all these considerations in mind, the conclusions by Montopoli et al. seem in contrast to many different published studies demonstrating that estrogens seem ‘protective’ of COVID-19 severity. Consequently, the suggestion to use SERM as a therapeutic option in COVID-19 is somehow hasty, above all considering the huge number of published studies reporting the opposite, i.e. that non-menopausal women show a quite low risk of developing COVID-19.
The supposed direct ‘protective’ effect of estrogens in non-menopausal women has to be definitely proven and of course other factors might be involved such as systemic risk factors and associated diseases that are more frequent in older menopausal women than in pre-menopausal women. Thus, the suggestion that estrogens might represent an ideal preventive treatment for COVID-19 has to be taken with caution.6 On the other hand, it cannot be excluded that the conclusions of Montopoli et al. are not due to a ‘protective’ role of antiestrogen therapy but due to other still unknown conditions of the patients, such as a blunted immune response due to cancer itself or associated chemo- and/or immuno-suppressive therapies, conditions that could reduce the so-called cytokine storm characterizing severe COVID-19 forms, thus leading to a milder disease. Nonetheless, all these observations should push researchers to investigate further the mechanisms leading to the lower prevalence of women among COVID-19 patients and above all the factors protecting pre-menopausal women.
Acknowledgments
Funding
None declared.
Disclosure
The authors have declared no conflicts of interest.
References
- 1.Montopoli M., Zorzi M., Cocetta V. Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients underwent anti-estrogenic therapy. Ann Oncol. 2021;32(5):676–677. doi: 10.1016/j.annonc.2021.01.069. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Abate B.B., Kassie A.M., Kassaw M.W. Sex difference in coronavirus disease (COVID-19): a systematic review and meta-analysis. BMJ Open. 2020;10:e040129. doi: 10.1136/bmjopen-2020-040129. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Channappanavar R., Fett C., Mack M. Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection. J Immunol. 2017;198(10):4046–4053. doi: 10.4049/jimmunol.1601896. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.EpiCentro COVID-19 integrated surveillance: key national data. https://www.epicentro.iss.it/coronavirus/sars-cov-2-sorveglianza-dati Available at: Accessed February 12, 2021.
- 5.Riggs B.L., Hartmann L.C. Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med. 2003;348(7):618–629. doi: 10.1056/NEJMra022219. [DOI] [PubMed] [Google Scholar]
- 6.Seeland U., Coluzzi F., Simmaco M. Evidence for treatment with estradiol for women with SARS-CoV-2 infection. BMC Med. 2020;18(1):369. doi: 10.1186/s12916-020-01851-z. [DOI] [PMC free article] [PubMed] [Google Scholar]